Hongxin Zhang
@HongxinZhang
Followers
124
Following
2K
Media
26
Statuses
492
Agreed. The value of PR descriptions is often in things that are NOT directly inferable from the changes: - What original problem led to this PR? - Are there related issues / prior discussions? - What alternatives have been tried? Does this supersede previous attempts? - Why are
Thank you GitHub, but that’s not how we build software. AI should help us focus more on reasoning, design, communication. Filter spam and unnecessary noise, not helping creating them.
21
115
1K
Excited to be heading to #AMPath24 soon! If you’re attending and want to talk about #OncoKB, let’s connect! I will be at our booth (#1421). Looking forward to it.
Join OncoKB Nov 19-23 at AMP 2024 in Vancouver! Stop by Booth 1421 to meet @HongxinZhang and @ritikakundra10, explore our latest developments & learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB! #AMPath24
0
1
1
Looking forward to #AMPath24 in November! Excited to meet colleagues and industry leaders, and share the latest from OncoKB. If you're attending, let's connect! #oncokb #precisiononcology
Join OncoKB Nov 19-23 at AMP 2024 in Vancouver! Stop by Booth 1421 to meet @HongxinZhang and @ritikakundra10, explore our latest developments & learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB! #AMPath24
0
0
1
New OncoKB data release v4.20 IDH1 R132 & IDH2 R172 L1 in astrocytoma & oligodendroglioma w/ Vorasidenib. Inavolisib L3A in PIK3CA onc mts in breast cancer. Removal of H3B-8800. CCNE1 amp, FBXW7 & PPP2R1A mts L3A in endo and ovarian cancer w/ Lunresertib+Camonsertib. And more!
0
3
6
New OncoKB data release v4.17: POLE/D1 exo dom mts and MSI-H L2 in CRC and SBC w/ pembro, nivo, ipi+nivo & dostar. MTAP del L3A in solid tumors w/ AMG193 & MRTX1719. ALK G1202R & L1196M L2 in NSCLC w/ lorl. Mobocertinib removal from L1 EGFR exon 20 in-frame ins in NSCLC & more!
0
3
6
Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!
0
2
4
New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes
1
6
18
New OncoKB data release v4.15: KRAS G12C Level 2 in amp cancer with sotorasib/adagrasib. Addition of new EGFR R2 resist. mts to osimertinib and Level 3A sensit. mts to afatinib. Removal of FGFR1 amp in LUSC based on limited response to FGFRi... and more, including 4 new genes!
0
10
21
Work on Open Source Software for a summer and support Cancer Research! Read more: https://t.co/Jmjg6lygbM
0
0
3
It has been a year since my last update on the prospective MSK-IMPACT/ACCESS sequencing cohort, now >120,000 tumor/cfDNA samples analyzed. Thanks to the patients, docs, nurses, techs, data scientists who have contributed. So where are we going next:
5
34
190
New release my @OncoKB people! Major updates: Removal of FGFR2-fusion+ #bladdercancer as L1 based on @US_FDA amendmt to erdafitinib label +MDM2 amplification➡️L3A in intimal-& lipo-sarcomas based on compelling clinical activity of MDM2-p53 antag milademetan&brigimadlin resp
0
6
21
New! Although #GenomicTests can lead to better outcomes in #CancerCare by informing #CancerRisk, prognosis, and therapeutic selection, they remain underutilized in routine #CancerCare. Find practical guidance from authors at https://t.co/a8sGlIwDEU
@OncoAlert
@MeliD32
2
85
157
Packed house at #AMPath23 to see 🌟 lead scientist @CDebyaniPhD present @OncoKB, the @US_FDA recognized cancer knowledge base, bringing precision oncology to patients at @MSKCancerCenter and now around the 🌏
0
14
43
Join us at the #AMP2023 to meet the team and explore the latest developments @ booth#928 ! Our team members @HongxinZhang and @ritikakundra10 will answer all your licensing and content questions! #AMP2023 #OncoKB #PrecisionMedicine #MSKCC
1
3
6
Check out @OncoKB 's new Precision Oncology Therapies page ( https://t.co/EriudIextU)! It's a great resource publically accessible on the OncoKB website, and here's why....
oncokb.org
OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.
2
7
19
News about work in @CD_AACR from @MSKCancerCenter: What Proportion of Cancer Patients May Benefit from Precision Oncology? More Than You Think!
mskcc.org
What proportion of cancer patients are eligible to benefit from precision oncology? There is an ongoing debate on this issue, partly due to a lack of consensus on which gene mutations are clinically...
1
6
41
Our new paper "Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer", is out in Cancer Discovery!
We are so excited that our work, Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer, is out in Cancer Discovery ( https://t.co/jIFewuZAG2)!
0
3
14
It's out y'all! A new @cbioportal paper! Super grateful for the opportunity to follow in the footsteps of @gaojj & @ecerami! The article highlights work from tons of people to improve joint longitudinal genomic & clinical data analysis in @cbioportal!
New cBioPortal paper by @inodb et al. in @CR_AACR Cancer Research: Analysis and visualization features for longitudinal genomic and clinical data from @AACR Project GENIE's Biopharma Collaborative (BPC). https://t.co/91dcPjPlG4
3
8
33